Last reviewed · How we verify
JNJ-90301900
At a glance
| Generic name | JNJ-90301900 |
|---|---|
| Also known as | NBTXR3, Functionalized hafnium oxide nanoparticles |
| Sponsor | Johnson & Johnson Enterprise Innovation Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (PHASE3)
- A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-90301900 CI brief — competitive landscape report
- JNJ-90301900 updates RSS · CI watch RSS
- Johnson & Johnson Enterprise Innovation Inc. portfolio CI